RU2016146097A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016146097A3 RU2016146097A3 RU2016146097A RU2016146097A RU2016146097A3 RU 2016146097 A3 RU2016146097 A3 RU 2016146097A3 RU 2016146097 A RU2016146097 A RU 2016146097A RU 2016146097 A RU2016146097 A RU 2016146097A RU 2016146097 A3 RU2016146097 A3 RU 2016146097A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461985381P | 2014-04-28 | 2014-04-28 | |
| US61/985,381 | 2014-04-28 | ||
| US201462047569P | 2014-09-08 | 2014-09-08 | |
| US62/047,569 | 2014-09-08 | ||
| PCT/US2015/027645 WO2015167968A1 (en) | 2014-04-28 | 2015-04-24 | Optically active pde10 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016146097A RU2016146097A (ru) | 2018-05-30 |
| RU2016146097A3 true RU2016146097A3 (cg-RX-API-DMAC7.html) | 2018-11-15 |
Family
ID=54359189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016146097A RU2016146097A (ru) | 2014-04-28 | 2015-04-24 | Оптически активный ингибитор pde10 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9493447B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3137461B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2017513913A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102558505B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106255690B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015253463B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016024523B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2946754C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2895487T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL248586B (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ716462A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2016146097A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015167968A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2544679T3 (pl) * | 2010-03-12 | 2019-10-31 | Omeros Corp | Inhibitory PDE10 oraz powiązane kompozycje i sposoby |
| NZ716462A (en) * | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| NZ716494A (en) * | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| US20160284909A1 (en) * | 2015-03-27 | 2016-09-29 | Gabriel Harley | Multi-diode solar cells |
| CA2980801A1 (en) * | 2015-04-24 | 2016-10-27 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| US9920045B2 (en) | 2015-11-04 | 2018-03-20 | Omeros Corporation | Solid state forms of a PDE10 inhibitor |
Family Cites Families (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK178590D0 (da) | 1990-07-26 | 1990-07-26 | Novo Nordisk As | 1,4-disubstituerede piperaziner |
| PT100905A (pt) | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
| RU95113454A (ru) | 1992-12-02 | 1997-06-10 | Пфайзер Инк. (US) | Катехольные диэфиры как селективные ингибиторы фдэiv, фармацевтическая композиция, способы лечения |
| DE4323192A1 (de) | 1993-07-10 | 1995-01-12 | Basf Ag | Verfahren zur Herstellung von Homo- und Copolymerisaten von Alk-1-enen |
| DE4325846C1 (de) | 1993-07-31 | 1995-01-19 | Herberts Gmbh | Verwendung von Furan-modifizierten aromatischen Pinakolderivaten als Initiatoren und Furan-modifizierte aromatische Pinakolderivate als solche |
| DE4343286A1 (de) | 1993-12-17 | 1995-06-22 | Hoechst Ag | Heteroaromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen |
| DE4409501A1 (de) | 1994-03-19 | 1995-09-21 | Didier Werke Ag | Verschleißfutter eines Schachtofens und Stein hierfür |
| AU695230B2 (en) | 1994-06-24 | 1998-08-06 | Euro-Celtique S.A. | Compounds for and method of inhibiting phosphodiesterase IV |
| US5789434A (en) | 1994-11-15 | 1998-08-04 | Bayer Corporation | Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors |
| TW332201B (en) | 1995-04-06 | 1998-05-21 | Janssen Pharmaceutica Nv | 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives |
| TW424087B (en) | 1995-04-06 | 2001-03-01 | Janssen Pharmaceutica Nv | 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives |
| US6037370A (en) | 1995-06-08 | 2000-03-14 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
| EA199800650A1 (ru) | 1996-01-22 | 1999-02-25 | Фудзисава, Фармасьютикал Ко., Лтд | Новые соединения |
| AU4015497A (en) | 1996-08-26 | 1998-03-19 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Thiazole derivatives useful as selective inhibitors of pde-iv |
| JPH1087543A (ja) | 1996-09-17 | 1998-04-07 | Chisso Corp | アルコキシベンゼン誘導体、液晶組成物および液晶表示素子 |
| US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| WO1999045914A1 (en) | 1998-03-13 | 1999-09-16 | Maruho Kabushikikaisha | Alkyl amine derivative and local anesthetic agent using the same |
| GB9807354D0 (en) * | 1998-04-07 | 1998-06-03 | Glaxo Group Ltd | Antiviral compound |
| SE9804212D0 (sv) | 1998-12-04 | 1998-12-04 | Astra Pharma Prod | Compounds |
| WO2000034251A1 (en) | 1998-12-07 | 2000-06-15 | Smithkline Beecham Corporation | A method for quantitative determination of amino acids |
| SI1165516T1 (sl) | 1999-03-12 | 2005-02-28 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterociklična sečnina in sorodne spojine, uporabne kot protivnetna sredstva |
| US7141593B1 (en) * | 1999-06-04 | 2006-11-28 | Abbott Laboratories | Pharmaceutical formulations |
| GB9929552D0 (en) | 1999-12-14 | 2000-02-09 | Proteus Molecular Design | Compounds |
| WO2001096334A2 (en) | 2000-06-15 | 2001-12-20 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| JP2004530703A (ja) * | 2001-05-22 | 2004-10-07 | ファイザー・プロダクツ・インク | 結晶形アジスロマイシン |
| US6821502B2 (en) * | 2002-06-12 | 2004-11-23 | Chevron U.S.A. Inc. | Method of making aluminum-containing zeolite with IFR structure |
| WO2004011410A1 (en) | 2002-07-27 | 2004-02-05 | Astrazeneca Ab | Chemical compounds |
| MXPA05003762A (es) | 2002-10-08 | 2005-07-22 | Scripps Research Inst | Inhibidores de hidrolasa de amida de acido graso. |
| WO2004041258A2 (fr) | 2002-10-30 | 2004-05-21 | Neuro3D | Utilisation d’inhibiteurs des phosphodiesterases des nucleotides cycliques, ayant une structure benzodiazepinique en therapie |
| TW200410921A (en) | 2002-11-25 | 2004-07-01 | Hoffmann La Roche | Mandelic acid derivatives |
| EP1568691A4 (en) | 2002-12-06 | 2010-08-25 | Kowa Co | ACCELERATOR FOR ERYTHROPOETIN PRODUCTION |
| MXPA05006727A (es) | 2002-12-20 | 2005-09-08 | Pharmacia Corp | Acidos heteroarilalcanoicos como antagonistas de receptor de integrina. |
| WO2004071509A1 (ja) | 2003-02-12 | 2004-08-26 | Nippon Chemiphar Co., Ltd. | オリゴデンドロサイト分化促進剤 |
| AU2004232973A1 (en) | 2003-04-18 | 2004-11-04 | Memory Pharmaceuticals Corporation | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
| AR047541A1 (es) * | 2004-02-13 | 2006-01-25 | Sandoz Ag | Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas |
| NZ550114A (en) | 2004-04-20 | 2011-02-25 | Transtech Pharma Inc | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
| US20060074102A1 (en) | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
| US7351833B2 (en) * | 2004-07-23 | 2008-04-01 | Abbott Laboratories | (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate |
| US7449486B2 (en) | 2004-10-19 | 2008-11-11 | Array Biopharma Inc. | Mitotic kinesin inhibitors and methods of use thereof |
| US8436176B2 (en) * | 2004-12-30 | 2013-05-07 | Medicis Pharmaceutical Corporation | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine |
| UA86283C2 (uk) | 2005-01-07 | 2009-04-10 | Пфайзер Продактс Инк. | Гетероароматичні сполуки хіноліну і їх застосування як інгібіторів pde10 |
| EP1850681B1 (en) | 2005-02-04 | 2019-12-18 | Firmenich Incorporated | Compounds comprising linked hetero aryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions |
| US20060252807A1 (en) | 2005-04-22 | 2006-11-09 | Kalypsys, Inc. | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders |
| UA91546C2 (uk) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| EP1928848A2 (en) | 2005-08-04 | 2008-06-11 | Apogee Biothechnology Corporation | Sphingosine kinase inhibitors and methods of their use |
| KR20080050577A (ko) * | 2005-08-29 | 2008-06-09 | 사노피-아벤티스 유.에스. 엘엘씨 | 피리다지노[4,5-ｂ]인돌 유도체의 신규 결정질 형태 |
| US7642246B2 (en) * | 2005-09-13 | 2010-01-05 | Sicor Inc. | Pure rocuronium bromide |
| SI1954684T1 (sl) | 2005-11-15 | 2014-07-31 | Otsuka Pharmaceutical Co., Ltd. | Oksazolna spojina in farmacevtski sestavek |
| EP1968946A4 (en) | 2005-12-23 | 2010-05-05 | Astrazeneca Ab | IMIDAZOLE AS MODULATORS OF THE GABA B RECEPTOR |
| JP2009535394A (ja) | 2006-05-02 | 2009-10-01 | ファイザー・プロダクツ・インク | Ｐｄｅ１０阻害剤としての二環式ヘテロアリール化合物 |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| US20080234345A1 (en) | 2006-09-08 | 2008-09-25 | Gene Logic Inc. | Method for reducing or alleviating inflammation in the digestive tract |
| SG185979A1 (en) | 2006-09-25 | 2012-12-28 | Ptc Therapeutics Inc | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
| EP2079462A4 (en) * | 2006-09-28 | 2009-12-02 | Merck & Co Inc | PHARMACEUTICAL COMPOSITIONS OF HDAC INHIBITORS AND CHELABLE METAL COMPOUNDS AND METALO HDAC HEMMER CHELATE COMPLEXES |
| WO2008040669A2 (en) | 2006-10-02 | 2008-04-10 | Janssen Pharmaceutica N.V. | Novel intermediates for the preparation of a glyt1 inhibitor |
| US7837978B2 (en) * | 2006-10-13 | 2010-11-23 | Chevron U.S.A. Inc. | Process for preparing aluminum-containing molecular sieve SSZ-26 |
| US7786139B2 (en) | 2006-11-21 | 2010-08-31 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| ES2624791T3 (es) | 2006-11-21 | 2017-07-17 | Omeros Corporation | Inhibidores de PDE10 y composiciones y métodos relacionados |
| PE20081506A1 (es) * | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
| WO2009008906A2 (en) | 2007-02-06 | 2009-01-15 | The Trustees Of The University Of Pennsylvania | Therapeutic compounds for blocking dna synthesis of pox viruses |
| AU2008253803A1 (en) * | 2007-05-22 | 2008-11-27 | Ultimorphix Technolgies B.V. | Tenofovir disoproxil hemi-fumaric acid Co-crystal |
| EP2017264A1 (de) | 2007-07-16 | 2009-01-21 | Bayer Cropscience Ag | Substituierte Phenylpropargylverbindungen, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren |
| WO2009049022A1 (en) | 2007-10-10 | 2009-04-16 | Ore Pharmaceuticals Inc. | Method for treatment of pancreatitis |
| TW200944520A (en) * | 2008-01-29 | 2009-11-01 | Glaxo Group Ltd | Spiro compounds as NPY Y5 receptor antagonists |
| WO2009143178A2 (en) | 2008-05-20 | 2009-11-26 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| US8377930B2 (en) | 2008-08-05 | 2013-02-19 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| PL2544679T3 (pl) * | 2010-03-12 | 2019-10-31 | Omeros Corp | Inhibitory PDE10 oraz powiązane kompozycje i sposoby |
| NZ716462A (en) * | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| NZ716494A (en) * | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
-
2014
- 2014-09-10 NZ NZ716462A patent/NZ716462A/en unknown
- 2014-09-10 NZ NZ630803A patent/NZ630803A/en unknown
-
2015
- 2015-04-24 CN CN201580023106.6A patent/CN106255690B/zh active Active
- 2015-04-24 BR BR112016024523-7A patent/BR112016024523B1/pt active IP Right Grant
- 2015-04-24 JP JP2016564604A patent/JP2017513913A/ja active Pending
- 2015-04-24 WO PCT/US2015/027645 patent/WO2015167968A1/en not_active Ceased
- 2015-04-24 ES ES15785340T patent/ES2895487T3/es active Active
- 2015-04-24 EP EP15785340.9A patent/EP3137461B1/en active Active
- 2015-04-24 US US14/696,295 patent/US9493447B2/en active Active
- 2015-04-24 CA CA2946754A patent/CA2946754C/en active Active
- 2015-04-24 KR KR1020167031125A patent/KR102558505B1/ko active Active
- 2015-04-24 AU AU2015253463A patent/AU2015253463B2/en active Active
- 2015-04-24 RU RU2016146097A patent/RU2016146097A/ru not_active Application Discontinuation
-
2016
- 2016-10-12 US US15/291,948 patent/US9850238B2/en active Active
- 2016-10-27 IL IL248586A patent/IL248586B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ES2895487T3 (es) | 2022-02-21 |
| IL248586B (en) | 2019-09-26 |
| US20170096420A1 (en) | 2017-04-06 |
| KR102558505B1 (ko) | 2023-07-21 |
| CA2946754C (en) | 2022-08-30 |
| US9493447B2 (en) | 2016-11-15 |
| CN106255690A (zh) | 2016-12-21 |
| AU2015253463A1 (en) | 2016-11-03 |
| US9850238B2 (en) | 2017-12-26 |
| EP3137461B1 (en) | 2021-08-11 |
| BR112016024523B1 (pt) | 2022-10-11 |
| RU2016146097A (ru) | 2018-05-30 |
| CN106255690B (zh) | 2020-07-17 |
| KR20160141845A (ko) | 2016-12-09 |
| WO2015167968A1 (en) | 2015-11-05 |
| NZ630803A (en) | 2016-03-31 |
| NZ716462A (en) | 2017-11-24 |
| AU2015253463B2 (en) | 2018-12-06 |
| JP2017513913A (ja) | 2017-06-01 |
| IL248586A0 (en) | 2016-12-29 |
| BR112016024523A2 (pt) | 2017-08-15 |
| US20160024070A1 (en) | 2016-01-28 |
| EP3137461A1 (en) | 2017-03-08 |
| CA2946754A1 (en) | 2015-11-05 |
| EP3137461A4 (en) | 2017-09-13 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20210505 |